Comparative Pharmacology
Head-to-head clinical analysis: DIPHEN versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHEN versus PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE.
DIPHEN vs PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors. It also exhibits anticholinergic, sedative, antiemetic, and local anesthetic effects.
Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, reducing allergic symptoms; it also has anticholinergic, antiemetic, and sedative effects. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects by central mechanisms.
50 mg IV/IM every 4 hours as needed for nausea/vomiting; 25-50 mg PO every 4-6 hours as needed for nausea/vomiting or motion sickness; 25 mg PO 3-4 times daily for vertigo; 15.6-25 mg IM/IV for antiemetic in surgery; maximum 300 mg/day.
Adults: 5 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4-6 hours as needed; maximum 30 mL per day.
None Documented
None Documented
Clinical Note
moderateDiphenoxylate + Torasemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide."
Clinical Note
moderateDiphenoxylate + Etacrynic acid
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid."
Clinical Note
moderateDiphenoxylate + Furosemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide."
Clinical Note
moderateTerminal elimination half-life is 22–72 hours (mean 30–40 hours); increases with hepatic disease or enzyme inhibitors.
Promethazine: 10-19 hours (range 5-30h); Codeine: 2.5-4 hours (rapidly metabolized); Clinical context: sustained antitussive effect from codeine despite short half-life. Half-life of promethazine extends with hepatic impairment.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for ~70% of eliminated drug; biliary/fecal excretion accounts for ~30%.
Renal: Codeine and metabolites ~90% (free and conjugated), Promethazine and metabolites primarily renal; minor biliary/fecal (<5% for codeine, ~6% for promethazine).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic
Diphenoxylate + Bumetanide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide."